424B5 filed Aug 10, 2026 at 07:39 ET
Replimune Group is conducting a $150 million underwritten public offering of 9,701,490 shares of common stock and pre-funded warrants to purchase 2,736,340 shares, priced at $12.06 per share, at-the-market. Net proceeds of ~$140.5 million will fund the commercial launch of TUDRIQEV (RP1), recently granted accelerated FDA approval, and continued development of the RPx platform. The offering was taken down from a shelf registration filed 17 days ago that had flagged a 30% overhang from Baker Brothers affiliates' resale registration and a going-concern warning with cash runway only through Q1 2027. This dilutive capital raise adds near-term downside, extending the runway but at the cost of ~13% dilution to existing shareholders, while the company has never generated product revenue and faces ongoing confirmatory trial requirements for TUDRIQEV's accelerated approval.